Company intelligence / Profile preview

PQ Bypass

Sunnyvale, California, United Statespqbypass.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

The company’s Detour System received FDA Breakthrough Device designation and demonstrated strong clinical results in published data with significant improvement for patients with long-lesion blockages. Clinical trials such as DETOUR2 and TORUS2 IDE were ongoing at the time of acquisition. The technology offers a minimally invasive alternative to open bypass surgery for complex PAD cases, reducing recovery times and improving outcomes[4][5][7].

Therapeutic areas: Cardiovascular
Modalities: DeviceMinimally invasive endovascular device therapy
Industry: Surgical Medical Devices

Partnerships

Deerfield Management Company (anchor investor and strategic partner)

Beyond the preview

Go deeper on PQ Bypass.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PQ Bypass.

Explore the full profile